Literature DB >> 2126836

Effects of erdosteine on sputum biochemical and rheologic properties: pharmacokinetics in chronic obstructive lung disease.

C F Marchioni1, M Moretti, M Muratori, M C Casadei, P Guerzoni, R Scuri, G B Fregnan.   

Abstract

Erdosteine is a new thioderivative endowed with mucokinetic, mucolytic, and free-radical-scavenging properties. This study evaluated (in a double-blind design vs. placebo) its efficacy on biochemical and rheologic properties of sputum and on some indices of respiratory function in chronic patients with chronic bronchitis (10 per group), while receiving basic treatment with a controlled-release theophylline preparation. The pharmacokinetics of erdosteine and theophylline were also studied. We found that a 2 week treatment with erdosteine (300 mg 3 times daily) was able to reduce significantly (p less than 0.05) the sputum apparent viscosity, fucose content, and macromolecular dry weight (MDW) with no statistically significant influence on sputum elasticity, DNA, albumin, total proteins, total IgA, lactoferrin, and lysozyme content. The treatment caused a significant increase in the following ratios: total IgA/albumin, lactoferrin/albumin, and lysozyme/albumin. The pharmacokinetics of erdosteine, its metabolites, and theophylline were the same after 1 or 14 days of treatment, evidence both of absence of an enzymatic induction and of an accumulation process. Further confirmation that there was no interference between erdosteine and theophylline was obtained from the data available on the group of patients receiving only theophylline, since its plasma levels and related pharmacokinetic parameters were identical to those obtained in patients receiving both drugs. In conclusion, 2 weeks of therapy with erdosteine reduced the marker of mucus glycoproteins (fucose) in patients with chronic bronchitis but did not interfere with the pharmacokinetics of xanthine derivatives. We also suggest that the significant increment in the IgA/albumin ratio might be related to a sum of other local effects such as reduction of the inflammatory process and enhancement of the humoral defense mechanism.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2126836     DOI: 10.1007/bf02719705

Source DB:  PubMed          Journal:  Lung        ISSN: 0341-2040            Impact factor:   2.584


  20 in total

1.  A STUDY OF URINARY AND SERUM LYSOZYME IN PATIENTS WITH RENAL DISEASE.

Authors:  D J PROCKOP; W D DAVIDSON
Journal:  N Engl J Med       Date:  1964-02-06       Impact factor: 91.245

2.  Erdosteine protection against cigarette smoking-induced functional antiprotease deficiency in human bronchiolo-alveolar structures.

Authors:  M Vagliasindi; G B Fregnan
Journal:  Int J Clin Pharmacol Ther Toxicol       Date:  1989-05

3.  Erdosteine protection from cigarette smoke-induced loss of alpha 1-antitrypsin activity in rat lungs.

Authors:  G L Biagi; G B Fregnan; G Gazzani; G Vandoni
Journal:  Int J Clin Pharmacol Ther Toxicol       Date:  1989-05

Review 4.  Bronchial mucus in health and disease.

Authors:  M T Lopez-Vidriero; L Reid
Journal:  Br Med Bull       Date:  1978-01       Impact factor: 4.291

5.  [Biochemical and rheological data in sputum. 3. Relationship between the biochemical constituents and the rheological properties of sputum (author's transl)].

Authors:  E Puchelle; J M Zahm; R Havez
Journal:  Bull Physiopathol Respir (Nancy)       Date:  1973 Mar-Apr

6.  Immunochemical quantitation of antigens by single radial immunodiffusion.

Authors:  G Mancini; A O Carbonara; J F Heremans
Journal:  Immunochemistry       Date:  1965-09

7.  Ultrasonic method of sputum homogenization and its application in the study of the enzymic content of sputum.

Authors:  F Girard; J M Tournier; J M Polu; E Puchelle; G Beck; P Sandoul
Journal:  Clin Chim Acta       Date:  1981-06-02       Impact factor: 3.786

8.  Effects of methylprednisolone on sputum biochemical components in asthmatic bronchitis.

Authors:  M Moretti; G Giannico; C F Marchioni; A Bisetti
Journal:  Eur J Respir Dis       Date:  1984-07

9.  Analysis of biological thiols: derivatization with monobromobimane and separation by reverse-phase high-performance liquid chromatography.

Authors:  G L Newton; R Dorian; R C Fahey
Journal:  Anal Biochem       Date:  1981-07-01       Impact factor: 3.365

10.  DL-S-(2-[N-3-(2-oxo-tetrahydrothienyl)acetamido])-thioglycolic acid: a novel mucolytic agent of the class of homocysteine thiolactone derivatives.

Authors:  M Gobetti; A Pedrazzoli; S Bradamante
Journal:  Farmaco Sci       Date:  1986-01
View more
  2 in total

Review 1.  Erdosteine.

Authors:  K L Dechant; S Noble
Journal:  Drugs       Date:  1996-12       Impact factor: 9.546

2.  Erdosteine reduces inflammation and time to first exacerbation postdischarge in hospitalized patients with AECOPD.

Authors:  Maurizio Moretti; Stefano Fagnani
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2015-10-28
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.